Delivery Order SPE2DB20D3101-SPE2DB25FRHR6
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 4, 2025, for the supply of XOLAIR 150 mg/ml syringes, with a contract ceiling value of $2,161.02 and a completion date of June 26, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded a delivery order valued at $8,644.08 to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/mL syringes, with an ultimate completion date of August 27, 2025. This is a competitively awarded, firm fixed-price delivery order with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child order under a larger contract vehicle, this delivery order falls under...
- The Defense Logistics Agency awarded a $72,034 delivery order to AmerisourceBergen Drug Corp on July 3, 2025, for the supply of Xolair 150 mg/mL syringes, with completion scheduled for July 25, 2025. This firm fixed-price, non-set-aside contract is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a $2,881.36 delivery order to AmerisourceBergen Drug Corp on June 27, 2025, for the supply of Xolair 150 mg/mL syringes, with completion targeted for July 21, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitive award under the company's existing contract vehicle with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving the federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xolair 150 mg/ml syringes, with a contract ceiling value of $5,402.58 and an ultimate completion date of August 19, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply vehicle...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on June 2, 2025, for the supply of Xolair 150 mg/ml syringes, with a firm fixed price ceiling value of $6,483.06 and an ultimate completion date of June 24, 2025. This non-set-aside, competitively awarded contract represents a single delivery order under the company's larger pharmaceutical supply framework with the federal government. The place of performance is listed as AmerisourceBergen's...
- The Defense Logistics Agency awarded a $30,254.28 firm fixed price delivery order to AmerisourceBergen Drug Corp for Xolair 150 mg/ml syringes, with an ultimate completion date of July 10, 2025. This non-set-aside contract was competitively awarded on June 17, 2025, with performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $10,805.10 to AmerisourceBergen Drug Corp for Xolair 150 mg/ml syringes, with an ultimate completion date of September 2, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a $34,576.32 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Xolair 150 mg/ml syringes. This non-set-aside competitive award is scheduled for completion by June 24, 2025, and represents a child delivery order under AmerisourceBergen's larger contract vehicle with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for...
- The Defense Logistics Agency awarded a $3,601.70 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for Xolair 150 mg/mL syringes, with an ultimate completion date of August 13, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRHR6Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,644.08 to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/ml syringes. This competitively awarded, firm fixed-price contract was issued on April 24, 2025, with an ultimate completion date of May 15, 2025. The contract will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen Drug Corp supplies an extensive portfolio of pharmaceutical products and medical supplies to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Xolair (omalizumab) is a biologic monoclonal antibody used primarily for the treatment of moderate-to-severe asthma and chronic idiopathic urticaria, making this delivery order part of AmerisourceBergen's ongoing support of specialized pharmaceutical needs across the military healthcare system. The contract included no set-aside designation and was competitively awarded, reflecting the company's demonstrated capability to meet federal procurement requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.6k | 4/24/25 |